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Abstract 
 
Background 
The effectiveness of the use of mammography as a medical screen for women aged 50-69 
is well-documented; however, there exists much uncertainty in the effectiveness of 
mammography screening for women aged 40-49.  Additionally, much uncertainty lies in 
the use of the PSA test as a medical screen.  The objectives of this study were (1) to 
determine the rates of PSA test and mammography test use and (2) to compare and 
contrast the factors that predict the use of mammography and the PSA test, respectively. 
Methods 
The Canadian Community Health Survey, Cycle 1.1 was used.  It is survey of 
approximately 133,300 people and it covers all health regions, provinces and territories.  
Probit regressions were used to analyze the statistically significant determinants of PSA 
test in men and mammography uptake in women.  Mammography uptake in women aged 
40-49 was also analyzed independently. 
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1 Introduction 
Breast cancer and prostate cancer are the two most frequently diagnosed cancers in 
Canadian men and women, respectively.  In 2004, an estimated 20,100 men will be 
diagnosed with prostate cancer and 21,200 women will be diagnosed with breast cancer. 
One in 8 men will develop prostate cancer during his lifetime and one in 9 women will 
develop breast cancer in her lifetime.  As such, there has been a tremendous effort by 
government, the medical community and non-profit organizations, such as the Canadian 
Cancer Society, to reduce the incidence of breast and prostate cancer.   
 
Early detection using screening procedures such as the Prostate Specific Antigen (PSA) 
test for prostate cancer or the mammogram for breast cancer are widely perceived to be 
beneficial - if you discover it early, then it can be treated early and you will live longer, is 
the usual refrain.  The goal of screening is to detect a condition before it produces 
symptoms.  They are usually quick, relatively painless and inexpensive.  If the screen is 
positive then the patient discovers the condition early, if it is negative then the patient is 
reassured.  So, on the face of the issue, screening seems to be highly desirable. 
 
This is, however, partly misleading.  Screening is a complex set of procedures that 
involves many tradeoffs and risks.  There are important costs – both financial and health, 
which make these procedures more controversial than is perceived by the general public.  
Mass screening for a disease involves testing a large number of people in order to detect a 
condition in a relatively small number of people.  Therefore, it is possible that the people 
who experience harm from the screening program far outnumber those who benefit. 
 
This paper examines the determinants of use of two of the most widely used medical 
screens – the mammogram, an X-ray used to detect breast cancer and the PSA test, which 
is a blood test used to detect prostate cancer.  It should be emphasized that the issues 
discussed in this paper relate to mass screening.  It is generally acknowledged that PSA 
testing and mammography are useful tools to detect the incidence and severity of prostate 
and breast cancer, respectively.  However, the use of the PSA test for mass screening in 
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men over 50 and the use of mammography in mass screening for women aged 40-49 is 
still controversial. 
 
The relevance of this study is threefold – first, to discuss the underreported downsides of 
screening; second, a literature review of previous research on determinants of medical 
screening; and third, an econometric analysis of the determinants of PSA testing and 
mammography in Canada.  Additionally, the determinants of use of the PSA test and 
mammography will be compared. 
1.1 Screening for Prostate Cancer – The PSA Test 
There are 2 main methods of screening for prostate cancer - the first is the Digital Rectal 
Examination (DRE), which is the most common and least expensive way to screen for 
prostate cancer. The other main medical screen for prostate cancer is the PSA test, which 
is a blood test to help detect prostate cancer. The PSA test measures a substance called 
prostate specific antigen made by the prostate. It is normal to find small quantities of PSA 
in the blood and levels rise with age. 
 
To confirm a case of prostate cancer, a biopsy and further imaging studies (X-rays, 
ultrasound, CT scans, MRIs) are performed.  Treatment options include surgery, radiation 
therapy and hormone therapy. 
1.2 Screening for Breast Cancer – The Mammogram 
There are three main methods of screening of screening for breast cancer – two are the 
Clinical Breast Examination and Breast Self-Examination, which are simply the 
procedures where a doctor or an individual manually examines the breast.  The third 
procedure is mammography, which is a type of x-ray that can see changes inside your 
breasts that are too small to feel.  
 
To confirm a case of breast cancer, a biopsy and further imaging studies (X-rays, 
ultrasound, CT scans, MRIs) are performed. Treatment depends on the grade and stage of 
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the cancer, as well as other factors such as the patient’s fitness.  Options include surgery, 
radiation therapy, chemotherapy and hormone therapy. 
1.3 Evidence for screening 
As with many medical procedures, the only way to determine the effectiveness of 
screening using the PSA test and mammography is with a comprehensive Randomized 
Control Trial (RCT), where one group of people is randomly assigned to the screening 
procedure and the other is not.  No comprehensive RCT has been yet completed for the 
PSA test.  Two are currently in progress: the European randomized study of screening for 
prostate cancer (ERSPC), which is scheduled to be completed in 2006, and the Prostate, 
Lung, Colorectal & Ovarian Cancer Screening Trial (PLCO), which is scheduled to be 
completed in 2015 (preliminary results available in 2006). 
 
Conversely, several RCTs have been performed for breast cancer screening 
(mammography) in Canada1 2, the USA3, Scotland4, and five trials in Sweden (the latest 
in Gothenburg5).  The general consensus is that screening results in a 20-30% reduction 
in mortalityi but the degree of effectiveness for different age groups, especially women 
aged 40-50 is uncertain5.  
 
This contrasts the degree of certainty regarding these two screening procedures: there is 
little knowledge of the benefits, risks and costs of the use of the PSA test as a screen, 
whereas there is strong evidence that the use of mammography in a mass screening 
program is beneficial. 
 
Although no RCT has been done to examine the effectiveness of PSA screening, there are 
several notable studies.  McDavid et al6 examined prostate cancer mortality and incidence 
in the U.S. in Canada over the last 30 years.  Canada and the U.S. experienced 3.0% and 
2.5% growth in age-adjusted incidence from 1969-90 and 1973-85, respectively.  Annual 
                                                 
i There are, however, detractors.  In an article that rocked the medical community, Gotzsche and Olsen6 
criticized the randomization methodology of 6 of the 8 major RCTs examining mammography for 
screening and concluded that “screening for breast cancer with mammography is unjustifiable”.  But, this 
opinion is in the minority. 
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age-adjusted mortality rates in Canada were increasing 1.4% per year from 1977-93 and 
then fell 2.7% per year from 1993-99.  They conclude that the incidence patterns 
observed between the U.S. and Canada suggest a strong relationship to PSA test use.  On 
the other hand, 3 “natural experiments” performed in the USA7 and Canada8 9 found that 
while the PSA test may be associated with a rise in incidence of prostate cancer, it is not 
associated with a decrease in mortality.  This suggests that many of the cancers that were 
detected and treated with the PSA test were clinically insignificant. 
 
As noted before, there has been no RCT for the PSA test, so one must be even more wary 
when analyzing incidence and mortality statistics for prostate cancer vis-à-vis the PSA 
test.  Reductions in mortality could be due to, for example, better treatment techniques.  
Additionally, there are less obvious sources of biases: 
 
1. Lead time bias - many cancers, especially prostate cancer, become more prevalent 
with age.  Autopsy studies have shown that up to 30% of men aged 50-70 have 
evidence of prostate cancerii.  Therefore, there are a large percentage of men who 
have prostate cancer, but it does not need to be treated because it never causes 
significant symptoms and did not pose an imminent danger.  To understand lead 
time bias, consider an example - a man undergoes screening and is diagnosed with 
prostate cancer at age 62 and subsequently dies at 70.  Another man does not opt for 
screening, however, at age 66 he develops symptoms and dies of prostate cancer at 
70.  Assume that both men had prostate cancer at the age of 62 but only the first 
man, who underwent screening, discovered it.  Notice that the treatment 
administered to the first man was not effective, i.e. he lived no longer than the man 
who did not undergo treatment.  However, for statistical purposes, his length of 
survival is 8 years whereas it is only 4 years for the second man.  Often, when the 
media reports of increasing survival rates due to screening, they do not take into 
account such possible lead time bias. 
2. Heterogeneity - Cancers are heterogeneous; they grow at different rates in different 
people. This heterogeneity leads to another bias – slow growing cancers are in a 
                                                 
ii Russell, p.28. 
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pre-symptomatic state for a longer period so they are more likely to be discovered 
during screening.  Consider another example – one man, who undergoes a PSA test 
screening yearly, is found to have a slow growing form of prostate cancer.  Another 
man, who also undergoes a yearly PSA test screening, does not discover his quick 
growing form of prostate cancer because it was too small to be detected during last 
year’s check-up but it progressed extremely quickly and symptoms developed 
before this year’s check-up.  The statistical bias is evident – slow growing cancers 
are more likely to be detected by screening than fast growing ones, thus giving the 
impression that screening reduces mortality. 
3. Natural History / Over-diagnosis – Doctors often tell their patients that ‘more 
men die with prostate cancer than of prostate cancer’.  This is because, in many 
instances, a cancer grows so slowly that it never becomes fatal or does not cause 
symptoms.  Therefore, screening can detect cancers that would never have caused 
symptoms, much less death.  The detection of such non-life threatening cancers will 
contribute to inflated survival statistics.  The over-diagnosis of prostate cancer, i.e. 
the proportion of cancers diagnosed by screening that would not have otherwise 
been detected during the individual’s life, has been estimated to be 29% in white 
men and 44% in black men10.  This over-diagnosis can possibly lead to unnecessary 
treatment, which can almost never be identified – i.e., it is impossible to prove, after 
the fact, that a prostatectomy was unnecessary. 
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2 Recommendations for Screening 
There exist many governmental and non-governmental organisations that review the 
evidence and make recommendations on preventative health and screening.  These 
include medical associations such as the American Medical Association and the Canadian 
Urological Association; and government associations such as Agence d’évaluation des 
technologies et des modes d’intervention en santé  (AETMIS) and the British Columbia 
Office of Technology Assessment. 
 
In the interest of brevity, I have included only the recommendations of two of the most 
respected governmental organisations - the Canadian Task Force on Preventive Health 
Care (CTFPHC) and the U.S. Preventative Services Task Force (USPSTF), and two non-
governmental organisations - the Canadian Cancer Society (CCS) and the American 
Cancer Society (ACS). 
 
The CCS is privately funded, non-profit organization, whose areas of interest are 
research, advocacy, prevention, information and support.  Its American counterpart, the 
American Cancer Society adopts a similar role in the United States. 
 
The CTFPHC is a government funded (by Health Canada) and managed organization 
whose stated mission is “to determine how the periodic health examination might 
enhance or protect the health of Canadians and to recommend a plan for a lifetime 
program of periodic health assessments for persons living in Canada”iii.  Similarly, the 
U.S. Public Health Service (Department of Health and Human Services) convened the 
USPSTF; its stated goal is to “evaluate clinical research in order to assess the merits of 
preventive measures, including screening tests, counseling, immunizations, and 
chemoprevention”iv. 
 
                                                 
iii http://www.ctfphc.org/ 
iv http://www.ahrq.gov/clinic/uspstfix.htm 
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The CTFPHC as USPSTF evaluate the evidence associated with preventative health care 
procedures and makes recommendations whether to incorporate these procedures in 
Periodic Health Examinations (PHE).  The system of ranking recommendations by 
degree of evidence available is described in 
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Appendix A. 
 
Table 1 shows the current guidelines for screening proposed by these four agencies.  Note 
that the government agencies are less enthusiastic than the non-profit agencies regarding 
the benefits of PSA screening in men and mammography screening in women aged 40-
49. 
Table 1 - Guidelines on PSA test and mammography for screening purposes 
 CTFPHC USPSTF CCS ACS 
P.S.A. Test 
 
• Don’t 
• Population:Men > 50 
• Insufficient 
• Population: Men  
• Discuss with doctor 
• Population: Men>50 
• Recommendv 
• Frequency : Yearly 
with discussion 
• Population : Men>50 
• Do 
• Population:Women 
50-69 
• Recommend 
• Frequency: every 2 
years 
• Population : Women 
50-69 
Mammogram 
 
• Conflicting 
• Population:Women 
40-49 
• Recommend 
• Frequency: 1-2 years 
• Population:Women >40 
• Discuss with doctor 
• Population : Women 
40-49 
• Recommend 
• Frequency : yearly 
• Population : Women 
>40 
 
It is clear from Table 1 that there is a great degree of uncertainty surrounding the use of 
the PSA test – the government agencies, which are usually assumed to act in the best 
interest of citizens, recommend against systematic screening of men using the PSA test.  
However, non-profit agencies such as the American Cancer Society recommend that men 
over 50 receive a PSA test regularly, or at least be given the option by their doctor. 
 
Conversely, all of the government and non-profit agencies in Table 1 recommend regular 
mammograms for women aged 50-69.  Note, however, that the Canadian agencies have 
some reservations about recommending mammography screening for women aged 40-49. 
 
                                                 
v For “high risk” cases.  Men>50 that are of “average risk” should be offered a yearly test by their doctor.  
“High risk” include African Americans and men who have a first-degree relative (father, brother or son) 
diagnosed with prostate cancer.  For a more complete definition of “high risk” and “average risk”, see the 
ACS website – http://www.cancer.org  
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In summary, there is much uncertainty surrounding the use of the PSA test as a medical 
screen, little uncertainty surrounding the use of mammography as a medical screen for 
women aged 50-69 and some uncertainty regarding the use of mammography as a 
medical screen for women aged 40-49. 
3 Issues surrounding PSA and mammography 
screening 
There are several factors that affect the decision whether to implement a mass screening 
program, as shown in Figure 1.  These factors are inter-related – for example, a change in 
the cut-off age for mass screening using mammography, i.e. from women aged 50+ to 
women aged 40+, affects the financial cost of the program and the number of people 
exposed to possible harmful effects. In addition, the effectiveness of the screen may vary 
by the age of the target group. 
 
Figure 1 – Issues surrounding screening programs 
3.1.1 Effectiveness of Screening 
For an effective program, the screen should be accurate, i.e. have a low rate of false 
positives (sensitivity) and false negatives (specificity).  A false positive is when the 
screen identifies someone as suffering from the disease when they are in fact healthy.  
Conversely, a false negative is when the screen does not identify the disease when it is in 
fact present in the individual. 
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The effectiveness of PSA testing is dependent on the cut-off level between “normal” and 
“abnormal” results.  The general consensus in the medical community is that 4 ng of PSA 
per ml or lower is “normal”.  Surprisingly, this level was originally proposed in 1986 by a 
private corporation, Hybritech (now Beckman Coulter)11.  This standard was later 
published in the New England Journal of Medicine12; however, there seems to have been 
little scientific research or cost/benefit analysis is determining this cut-off.  The fact that 
the “normal” level of PSA increases with agevi exacerbates the problem of determining 
the cut-off level. 
 
A similar cut-off conundrum is present in screening for breast cancer – there is 
disagreement whether mammography screening should begin at age 40 or at age 50 in 
women1. 
 
Ultimately, to determine the effectiveness of a screening program, a RCT must 
demonstrate improved health outcomes.  This has yet to be done conclusively for both the 
PSA test in men and mammography in women aged 40-49. 
3.1.2 Harmful effects 
The cut-off levels for screening directly impact the harm caused to individuals.  For 
example, if a new consensus was reached and a “normal” PSA reading went from 4ng/ml 
to 10ng/ml, then this would have a major impact on false positives and false negatives.  
Presumably, the rate of false positives would decrease, sparing many men the anxiety of a 
biopsy and potential unneeded treatment.  But, the rate of false negatives would likely 
increase and more relevant cases of prostate cancer would avoid detection.   
 
The rate of false-positives for PSA test results of between 4.0ng/ml and 9.9ng/ml is 
88%13, i.e. only 22% of patient’s with PSA test readings between 4.0 and 9.9 ng/ml are 
subsequently found to have prostate cancer with a needle biopsy.  The rate of false 
negatives, i.e. those with a PSA level of 4ng/ml or below but who are subsequently found 
to have prostate cancer, is up to 12.5%13.  A recent influential study14 in the New England 
                                                 
vi Mokete et al. [2003] notes that a normal PSA range for a man aged 40-49 is 0 to 2.5 ng/ml, whereas a 
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Journal of Medicine has highlighted the issue of false negatives associated with PSA 
testing and concluded that “Biopsy-detected prostate cancer, including high-grade 
cancers, is not rare among men with PSA levels of 4.0 ng per millilitre or less”.  
 
The harmful effects of false positives and false negatives are significant - false positives 
cause people a high level of anxiety, which does abate immediately even when 
subsequent tests show that the disease is not present.15  If a false positive results in 
unnecessary treatment or surgery, then the individual is exposed to possible serious side 
effects such after prostate cancer surgery, such as impotence and incontinence.  But the 
medical communityvii is generally aware that the PSA test is controversial; as such, the 
test is rarely used to determine if a man does or does not have prostate cancer, but rather 
acts as a gatekeeper for biopsies, which are required to confirm the disease.  The 
probability that a false positive test leads to an unnecessary biopsy is itself dependent on 
how the doctor uses the total PSA level provided by the test, in addition to other 
information such as the patient’s age, free PSA level, PSA velocity, gland volume and 
digital rectal exam.  
 
False negatives are also harmful – a man or woman who undergoes screening that does 
not detect his/her condition feels cheated; this can also result in potential legal action and 
may undermine public confidence in the screening program16. 
 
When considering screening, it is important to consider risks not only for a single screen, 
but the cumulative risks for the series of tests after the recommended age.  For example, 
women who follow the guidelines of the American Cancer Society have a 43% chance of 
eventually experiencing a false-positive test17.  Elmore et al.18 estimated that 49% of 
women who undergo screening will experience at least one false-positive during ten 
rounds and that 19% will be subjected to an unnecessary biopsy.   
                                                                                                                                                 
normal range for a man aged 70-79 is 0-6.5 ng/ml. 
vii See Table 10 
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3.1.3 High and informed uptake  
The success of a screening movement depends on the participation of the target group.  
The most important factor in determining whether an individual participates in a 
screening program is their perception of the worth and efficacy of the program.  
However, even if there was an accord by physicians and health organizations on the value 
of certain screening procedures, individuals may not comply with themviii - uptake is also 
dependent on other factors such as high anticipated or actual pain, discomfort or 
embarrassment30. 
 
The considerable uncertainty and lack of RCT evidence on the usefulness of mass 
screening using the PSA test in men and mammography in women (aged 40-49), has 
introduced an important ethical question: should doctors require informed consent from 
their patients before performing these tests? 
 
Informed consent usually means a deliberate process that includes a written, as opposed 
to verbal, agreement.  There are theoretical benefits to informed consent for both the 
provider and patient – the provider is somewhat protected from accusations of 
malpractice, which is especially important in the US19.  The patient, for his part, is 
provided with information on the benefits and risks associated with screening and the 
autonomy to make his own decision, which partly solves the ethical dilemma of the 
physician.  Informed consent requires time for the physician to explain complicated 
medical issues to patients – time that many busy physicians do not have20, therefore, it is 
usually only done in research context (i.e. new cancer trials), where the risk of adverse 
outcomes is relatively high because the procedure does not have an established clinical 
benefit; the PSA test does not yet have an established clinical benefit, however, the 
medical community had not deemed the risk of adverse outcomes to be “high”.  This is 
perhaps because a biopsy is required to confirm prostate cancer after a positive PSA test.  
                                                 
viii Byrne and Thompson [2001] 
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3.1.4 Effectiveness of treatment 
If there is no effective treatment for a condition, then a screening program is useless - the 
target group will incur major psychic costs with no benefits21.  To justify a mass 
screening program, the treatment must additionally be more effective when administered 
early.  Fortunately, there are treatment programs for prostate and breast cancer, such as 
surgery, radiation and hormone therapy – all these treatment options are more effective 
when administered early. 
3.1.5 Cost 
Health care costs are substantial in Canada – in 2002, total health care costs were 9.6% of 
GDP, 70% of which was public sector spendingix.  In addition to financial concerns, 
health spending has important political ramifications – the solvency of the public medical 
system is one of the highest priorities for Canadians. 
 
Screening programs are generally large and divert scarce funds from other areas of the 
health care system.  As such, the cost carefully examined and compared with alternatives. 
 
4 Cost-Effectiveness Analysis in Health Economics 
Cost-effectiveness analysis (CEA) is a method of comparing the relative value of various 
clinical strategies.  Usually considered as a ratio, the cost effectiveness a procedure 
relates the cost of that procedure to the health benefits resulting from it. In health terms, it 
is often expressed as the cost per year per life saved or as the cost per quality adjusted 
life-year saved.   It is similar to the more popular cost-benefit analysis (CBA) - the 
primary difference being that CBA refers to the evaluation of benefits and costs, which 
are both measured in monetary terms; whereas, CEA refers to the evaluation of 
alternatives using their costs and effects of producing some desired outcome.  Using 
CEA, two strategies are compared using the following ratio: 
 
                                                 
ix OECD Health Data 2004, 1st Edition 
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The CE ratio represents the cost of switching from the current practice to the new 
strategy divided by the change in effect of switching from the current to the new practice.  
The lower the cost and the greater the positive change in effect, the more cost-effective is 
the new strategy. 
 
The effectiveness of health interventions are usually associated with their effect on life 
expectancy, i.e. by how many years does a particular medical treatment or testing strategy 
lengthen one's life?  This, however, does not take into account the quality of life that 
individuals derive from these additional years of life.  The metric that is commonly used 
to incorporate quality of life into the analysis is the Quality-Adjusted Life-Year (QALY).  
The estimation of quality-of-life weights that reflect the satisfaction derived from various 
health states is required to determine the QALYs produced by a medical treatment.  
These weights vary for each individual; however, health service researchers have 
attempted to quantify these using various methods such as self-evaluation and observed 
behaviour. 
 
One of the salient features of medical interventions is the presence of uncertainty.  Costs 
can be relatively easily measured; however, the health effects are much more difficult to 
quantify.  For example, in the case of PSA testing, prostate cancer prevalence, death rate, 
treatment results, mortality and the discount rate are all associated with at least some 
uncertainty.  Variations in all or any of these variables have a major impact on the CEA 
analysis.  To allow for this variance in possible results, most researchers use sensitivity 
analysis.  This involves determining a reasonable range over which the parameters might 
vary.  The most likely value is the baseline value.  In cases where there is only one 
variable for which the value is uncertain, the process is straightforward - separate CEA 
analyses are performed using the baseline value, the "high" value and the "low" value.  
When there are several uncertain variables, the process becomes more complex.  There 
could be many possible CEA results depending on the values of individual variables.  In 
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such cases, simulation techniques such as Monte Carlo analyses, which randomly 
generate values for uncertain variables repeatedly to simulate a model, are employed. 
 
Another challenge in performing cost-effectiveness analyses of health interventions is the 
modelling of the natural history of the disease.  Markov models are most often used, with 
several health states and probabilities associated with transfer between states.  A simple 
model is shown below: 
 
  
Markov models can be made more complicated; however, they can never perfectly model 
the natural history of the disease because the transitions between states are discrete, 
whereas the transition in reality is continuous.  More transition states can be added but 
transition probabilities become increasingly more difficult to quantify because of lack of 
medical evidence. 
 
A screening program that has a favourable cost-effectiveness analysis in one country may 
not have one in another country due to variations in the screening interval or target 
population.  For example, the Canadian Cancer Society recommends that women 50-69 
years of age undergo a mammogram every two years, whereas the American Cancer 
No Cancer 
 
Stage 1 cancer 
 
Stage 2 cancer 
 
Mortality due to cancer 
 
Mortality not due to 
cancer 
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Society recommends yearly mammograms.  The cost difference associated with the 
screening interval could prove to be prohibitively high.  Additionally, the organization of 
the health care system would have an effect: in Canada, user charges are not permitted, 
whereas they are in the US.  This would also have an effect of cost and on uptake of the 
screening procedure.   
 
Analyses can be performed from the societal perspective or from the individual 
perspective.  The vast majority of cost-effectiveness analyses are generally used to make 
public policy decisions; therefore, the societal perspective is most often examined.  Such 
analyses usually ignore individual costs such as psychic costs associated with a false 
positive.  These costs, though not quantifiable, can be very important and should also be 
taken into consideration, if possible. 
 
4.1 CEA of mammography - Salzmann et al. 22 
Salzmann et al. performed a cost-effectiveness analysis of mammography screening 
programs.  Previous research had shown that mass screening using mammography can be 
achieved at a reasonable cost for women aged 50-6923 24.  Salzmann et al. added to the 
literature by performing an analysis that included women aged 40-49.  Because CEA 
involves marginal costs and benefits, the choice of which strategies to compare affect the 
results of the analysis and, potentially, the conclusion.  For example, a previous study 
performed a CEA analysis for a screening program for women aged 40-69 vs. no 
screening program at all25.  Most of the benefits of this program may have accrued to 
women aged 50-69 and not those aged 40-49; therefore, the question of whether 
screening women aged 40-49 was not properly addressed.  Other analyses have examined 
the incremental benefits for women aged 40-4926 – their methodology is similar to that of 
Salzmann et al.  Salzmann et al. used a Markov model that examined women undergoing 
the following breast cancer screening strategies: 
1. No screening. 
2. Screening biennially from 50 to 69 years of age 
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3. Screening every 18 months from 40 to 49 years of age, followed by screening 
biennially from 50 to 69 years of age. 
 
Using information derived from the medical literature on the benefits, costs and mortality 
rates, Salzmann et al. found the cost-effectiveness of screening 50- to 69-year-old women 
to be $21,400 per year of life saved and the incremental cost-effectiveness of screening 
40- to 49-year-old women to be $105,000 per year of life saved.  They noted that the 
choice of discount rate had a considerable effect on cost-effectiveness ratios – an increase 
in discount rate alters the CEA ratio because it reflects the lower economic value of an 
expense that is delayed and the higher value of a benefit that is realized sooner. 
 
It is also interesting to examine the disaggregated benefits - If 10000 40-year-old women 
did not undergo screening mammography at all, 308 would die of breast cancer by 80 
years of age. A total of 3546 would die of other causes. A biennial screening 
mammography program applied to this cohort from 50 to 69 years of age would avert 37 
deaths; 52 deaths from breast cancer would be prevented, but 15 of these women would 
die of other causes by 80 years of age. Expanding the screening program to include 
every-18-month screening for 40- to 49-year-old women would avert an additional 4 
deaths (for a total of 41); 6 deaths from breast cancer would be prevented, but 2 of these 
women would die of another cause by 80 years of age.   
4.2 CEA of PSA test - Ross et al. 27 
Although studies do exist on the cost-effectiveness of screening using the PSA test, the 
value of such studies is questionable because the benefits of prostate cancer screening 
have not yet been proved or quantified.  Ross et al. performed a Monte Carlo analysis on 
a Markov model to determine the cost-effectiveness of various PSA screening strategies.  
They determined that rather than starting a screening strategy at age 50, a more cost-
effective program would start at an earlier age but screen biennially instead of annually.  
But, because the results of the RCTs of the PSA test are not yet available, this study is 
susceptible to biases described in Section 1.3 and, furthermore, they cannot conclude that 
this strategy is better than no strategy at all. 
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5 Previous Research on Determinants of Screening 
Patient and doctor factors that affect the decision to undergo screening are listed in Table 
2. It is difficult to empirically examine some of the determinants - for example, it is 
impossible to quantify the effect of the media on the decision for individuals to undergo a 
PSA test or mammography.  
 
Table 2 – Determinants of decision to undergo screening 
Patient Factors Doctor Factors 
• Patient-doctor relationship 
• Health benefits and costs 
• Expectations • Perception of guidelines 
• Anxiety • Clinical practice experience 
• Peers • Influence of colleagues 
• Media • Media / Lobbying 
• Family history • Time required to explain and order test 
• Demographic factors – Age, race, income, 
education etc. 
 
• Other costs  
1. Opportunity costs for time lost on job  
2. Psychic costs - anxiety associated with 
undergoing a procedure. exacerbated by 
false positives. 
 
3. Financial cost, if applicable  
 
Below are some of the findings of previous analyses on the determinants of undergoing 
screening. 
 
Health benefits and costs – Both the patient and doctor are attempting to maximize the 
benefits associated with medical screening.  This may or may not increase the use of 
medical screens, depending on the risks associated with screening and the evidence that 
screening improves health outcomes.  The funding agency is also concerned with 
maximizing benefits, but it is also attempting to minimize costs.  This may either increase 
screening to reduce long-run costs or it may reduce unnecessary screening. 
Patient-doctor relationship43 – It has been shown that a good patient-doctor relationship 
can lead to fewer medical screens. 
Expectations28 – An individual’s perceptions and knowledge of the condition as well as 
the nature and consequences of the screening process affect uptake.  Individual 
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perceptions of risk may be biased29, which results in too much or too little demand for 
screening. 
Anxiety - Low-perceived need and unpleasantness of the procedure reduce uptake of 
screening30.   
Peers31 - Personal experience of the disease via friends and family increase uptake.   
Media – The media plays an important part increasing awareness of cancer and screening 
options. 
Family History32 – As with all cancers, genetic predisposition is a significant determinant 
of risk.  People who have a family history of prostate or breast cancer derive higher 
expected benefits from P.S.A. tests and mammograms than the general population. 
Race33 – For prostate cancer, men of African descent are at a higher risk than the general 
population.  For breast cancer, Ashkenazi Jews are at higher risk.  As with family history, 
it is reasonable to expect that people who derive the most benefit from screening would 
be more likely to undergo such tests. 
Income / Economic Status34 – Sensitivity to monetary and time costs is dependent on an 
individual’s economic status. 
Education35 – Individuals with more education may be better informed on the potential 
benefits and drawbacks to screening. 
Employment status36 – Individuals who work have a higher opportunity cost of going to 
the doctor than retired or stay-at-home people. 
Intrinsic utilization37 – People use varying amounts of health care.  Even in Canada, 
where health care is free (with some exceptions) and readily available; some people 
choose to not use the health care system, whereas others are high users. 
Expected longevity38 – Expected longevity has positive effects on demand for some 
medical screens. 
Age6 – The utility associated with health care may vary with age. 
Healthy behaviour39 – There are people who engage in healthy habits, such as regular 
exercise, a balanced diet and non-smoking.  Such people, who are especially health 
conscious, may be more likely to undergo medical screens. 
Risk preference38 - Risk aversion may have an impact on uptake of screening tests. 
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Health Status42 – Rehabilitation and treatment may be more difficult for people that are 
already sick, therefore, they have may have a higher cost to getting other diseases and 
may be more likely to engage in medical screening.  Additionally, such people have 
regular contact with health professionals, who might include medical screens in the 
course of treatment for an unrelated condition.  Conversely, people that are already sick 
may have physical limitations and thus less likely to visit their doctor for medical 
screens. 
Time costs40 - Limited access to transportation or not being able to take time off work 
affects the uptake of screening. 
5.1 Review of empirical evidence – Jepson et al.41 
Jepson et al. provide a review of the empirical literature on the determinants for screening 
uptake.  They reviewed four studies (two “controlled” trials and two cohorts) that 
examined screening tests for prostate cancer.  The four studies were published from 
1993-1998 and were done in the USA.  All four studies examined the DRE; two of the 
four additionally examined the PSA test.  Three of the studies examined primarily 
African-American men.  Although the studies are far from perfectx, their conclusions are 
nonetheless worth examining.  They are shown in Table 3: 
Table 3 – Determinants of PSA screening 
Category Determinant Studies in which 
found significant at 
5% level 
Individuals with the following determinants are more likely to attend screening 
Socio-Demographic Having higher level of education 2/3 studies 
 Being older than 65 years 1/4 studies 
Individuals with the following determinants are less likely to attend screening 
Socio-Demographic Being African-American 2/3 studies 
 
Jepson et al. also examined 34 breast cancer screening studies (16 RCTs, four controlled 
trials, four quasi-RCT studies, nine cohorts and one case-control study).  19 of the studies 
were published from1995-2000 and 15 were published before 1994.  29 of the studies 
were done in the USA, two in the U.K., two in Australia and one in Italy.  One of the 
studies examined physician factors while the rest examined patient factors.  The studies 
                                                 
x Jepson et al. [2000], p. 35 
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were carried out by a variety of organizations – health maintenance organizations 
(HMOs), primary-care practices, community screening programmes, hospitals, 
universities and other organizations.  16 of the 34 studies included women aged 40-49; 
eight studied only women aged 50+; three of the studies targeted only women aged 60+. 
 
The determinants of whether a women participates in mammography screening are 
shown in Table 4: 
Table 4 – Determinants of mammography screening 
Category Determinant Studies in which 
found significant 
at 5% level 
Individuals with the following determinants are more likely to attend screening 
Socio-Demographic Having insurance 7/12 studies 
 Being black 3/15 studies 
 Being African-American 1/15 studies 
 Being White 1/15 studies 
Knowledge, behaviour, attitudes and beliefs Having had previous mammogram 13/20 studies 
 Expressing and intention to attend 
screening 
6/11 studies 
 Having had a previous Pap smear 1/3 studies 
 Perceiving own health to be poor 1/4 studies 
 Knowing about mammograms 1/5 studies 
 Perceiving self to be susceptible or 
vulnerable to cancer 
1/8 studies 
Health Visited GP ≤ 7 times in preceding year 2/5 studies 
 Having a family history of breast 
cancer 
3/9 studies 
 Being at moderate risk of breast cancer 
developing 
1/3 studies 
 Having a history of ≥ 2 major illnesses 1/4 studies 
 Having a history of breast cancer 1/4 studies 
 Visiting GP 4-6 times in preceding year 1/5 studies 
Barriers and facilitating conditions Receiving recommendation from 
doctor 
2/4 studies 
 Being worried about breast cancer 1/5 studies 
Individuals with the following determinants are less likely to attend screening 
Socio-demographic Being Native-American 1/15 studies 
Knowledge, behaviour, attitudes and beliefs Being a smoker 1/3 studies 
Barriers and facilitating conditions Having concerns about radiation and 
mammography 
1/5 studies 
Determinants where the effects are unclear (i.e. studies found positive and negative effects) 
Socio-demographic Age 12/31 studies 
 Being single, divorced or widowed 3/11 studies 
 Having a higher level of education 3/18 studies 
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5.2 Sickness - Wu42 
Wu [2003] analyzes the relationship between health status and the likelihood of engaging 
in medical screening and other preventative behaviour, in particular flu shots, cholesterol 
checks, mammograms, breast examinations and prostate examinations. 
 
Wu uses two independent datasets – the Health and Retirement Studyxi and the Medical 
Expenditure Panel Surveyxii, restricted to individuals aged 40-70. 
5.2.1 Results 
Wu found that people with higher education, higher incomes and insurance coverage are 
more likely to engage in these screens and preventative measures.  Preventative 
behaviour is also positively related to age and the number of doctor’s office visits in the 
last year.  Wu also finds that blacks are more likely to have mammograms. 
 
As noted before, this article is particularly interested in the relationship between health 
status and the likelihood of receiving medical screens.  To examine this relationship, Wu 
uses several different measures of health status – self-reported health, and index of 
limitations in activities of daily living (ADLs) and specific medical conditions such as 
heart disease, lung disease and diabetes. 
 
Initially, Wu created a binary variable, “sick” to be 1 if an individual reported their health 
as being either fair or poor.  The probit coefficients imply that being in fair or poor health 
decreases the probability of getting a mammogram by 4 percentage points and decreases 
the probability of getting a prostate examination by 7 percentage points (coefficients 
significant at 5% level).  This demonstrates that even after controlling for other 
determinants, health status is a significant predictor of screening. 
 
Wu puts forth several reasons why those in poorer health would be less inclined to 
engage in mammography and prostate examinations, including: sicker people avoid 
                                                 
xi Conducted by University of Michigan Institute for Social Research, http://www.isr.umich.edu/ 
xii Conducted by the Agency for Healthcare Research and Quality (AHRQ), http://www.ahcpr.gov/ 
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screening because they are more afraid about learning about yet another condition or that 
sick people may discount the future more than healthy people.  To further study these 
hypotheses, Wu examines the relationship between getting screens and expectations of 
the future.  The HRS asked several questions that determined an individual’s degree of 
pessimismxiii.  When controlling for pessimism, Wu finds that poor health decreases the 
likelihood of women having monthly breast examinations and men having prostate 
checks only for people who have pessimistic expectations of the future.  This suggests 
that psychological factors may be an important pathway on how sickness decreases the 
probability of undergoing screening. 
5.3 The Physician’s perspective - Tudiver et al.43 
Most analyses, only take into account the patient’s characteristics. In medical decision 
making, however, variables associated with the doctor, such as beliefs, knowledge and 
attitudes is equally, if not more important.  Tudiver et al., using a survey of Canadian 
physicians, examined physician practices when the guidelines for screening procedures 
are uncertain.  Tudiver et al. defined an “unclear” guideline as one having a C 
recommendation (insufficient evidence to recommend) from the Canadian Task Force on 
Preventative Health Care (CTFPHC).  A “conflicting” guideline was one for which there 
were different recommendations from at least 2 different organizations for the same 
procedure.  PSA test and mammography are two such procedures that have unclear and 
conflicting guidelines. 
 
The survey of physicians was done using a 2-part questionnaire:  the first part asked a 
series of questions on physicians’ perceptions of guidelines and the second part described 
a series of clinical case vignettes.  These vignettes described hypothetical patients, along 
with their symptoms, attitudes, demographic features and expectations.  Based on this 
information, a physician decided whether to order the medical screen or not.  A sample of 
a clinical case vignette provided by Tudiver et al. is in Appendix B. 
 
                                                 
xiii Questions include “What do you think the chances are that the US economy will exhibit a major 
depression sometime in the next 10 years or so?”  Wu claims that there is evidence for a correlation 
between indices of pessimism, in this case pessimism about the economy and pessimism about health. 
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Table 5 shows that the physician responses to part 1 of the questionnaire were in line with 
the CTFPHC task force, i.e. a majority believed that the guidelines were conflicting were 
PSA screening and mammography screening for women aged 40-49. 
Table 5 – Physician perceptions of guideline recommendations 
 Physician’s perception of guideline (%) 
Screening Test Recommend 
to screen 
Recommend to 
not screen 
No clear 
recommendation 
Feels guidelines 
are conflicting 
PSA for Men >50xiv 17.9 45.0 37.0 86.6 
Mammogram for 
Women 40-49xv 
25.4 51.0 23.6 67.5 
 
Table 6 shows that factors such as patient anxiety and expectations and family history all 
had a significant impact on the odds that a physician would recommend a PSA test or 
mammogram.  The impact of family history was very significant for mammography.  It is 
also interesting to note that a good patient-physician relationship halved the odds of a 
mammogram being ordered for women aged 40-49.  Tudiver et al. hypothesize that “in a 
good patient-physician relationship, patient and physician are more likely to discuss the 
pros and cons of a conflicting screening guideline and to find common ground than when 
the relationship is poor.”  However, this phenomenon is not seen in men vis-à-vis the 
PSA test.  Tudiver et al. conclude that this may “due to the unique character of the 
relationship male patients have with their physicians.” 
Table 6 – Determinants of physician decision to refer for medical screens 
Decision to refer for PSA, age 50+ Odds Ratio 95% CI 
Patient anxiety present 1.8 (1.2, 2.9) 
Patient expectations present 7.4 (4.3, 12.7) 
Family history present 4.0 (2.6, 6.3) 
Perceive PSA screening recommended 4.3 (1.5, 12.3) 
Perceive PSA screening is not recommended 0.3 (0.2, 0.5) 
Agree PSA does more harm than goodxvi 0.3 (0.2, 0.6) 
Agree: influence of colleaguesxvii 1.9 (1.2, 3.2) 
Decision to refer for mammogram, age 40-49   
Patient anxiety present 3.0 (1.5, 6.1) 
Patient expectations present 2.4 (1.1, 5.0) 
Family history present 32.0 (14.1, 72.8) 
Good patient-physician relationship 0.5 (0.2, 1.0) 
                                                 
xiv As shown in Table 1, the CTFPHC recommends to not perform. 
xv As shown in Table 1, the CTFPHC cites insufficient evidence and makes no recommendation. 
xvi Reference group: those who disagree that screening test causes more harm than good. 
xvii Reference group: those who disagree that practice of colleagues influence decision to order screening 
test. 
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Perceive mammography recommended 3.0 (1.1, 8.0) 
Perceive mammography is not recommended 0.5 (0.1, 0.6) 
Agree mammography does more harm than goodxvi 0.5 (0.2, 1.0) 
Agree: influence of colleaguesxvii 2.5 (1.2, 5.1) 
 
In addition, physician factors are very important in the decision to screen: the physician’s 
perception of the recommendation of the test, the perception of harm and the influence of 
colleagues all had a significant effect. 
 
Perhaps most importantly, the results of Table 6 show that physicians are strongly 
influenced by the practices of their colleagues; Tudiver et al. note that social influences 
play an important role in influencing screening decisions, particularly when uncertainty is 
high. 
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6 Determinants of PSA test and mammography use 
6.1 Data and Empirical Strategy 
The data source used to analyze the determinants of undergoing medical screens is the 
Canadian Community Health Survey, Cycle 1.1.  The CCHS is a nationally 
representative, cross-sectional survey of approximately 133,300 people.  The survey is 
weighted, stratified and clustered.  More information on the CCHS and method of 
collection is in Appendix D.   
6.2 Results and Analysis 
Table 7 summarizes the basic demographic information for the CCHS sample.  Only 
approximately one third of men over 40 had a PSA test in the last 12 months and one 
third of women over 35 have had a mammogram in the last 12 months.  Almost half of 
respondents were married.  Slightly over half of respondents were employed. 
Table 7 – Summary statistics 
Variable CCHS (population) value 
Age (proportion)  
12-19 0.13 
20-29 0.16 
30-39 0.18 
40-49 0.20 
50-59 0.14 
60-69 0.09 
70+ 0.10 
Sex (proportion men) 0.46 
Visible Minority (proportion) 0.14 
Employed (proportion) 0.54 
Education (proportion)  
Less than secondary school 0.30 
Secondary school grad 0.19 
Some post-secondary 0.08 
Post-secondary grad 0.43 
Marital Status (proportion)  
Single 0.30 
Common-law 0.08 
Widowed/Separated/Divorced 0.12 
Married 0.49 
Income (proportion)  
No income 0.01 
Less than $15,000 0.08 
$15,000 to $29,999 0.08 
$30,000 to $49,999 0.23 
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$50,000 to $79,999 0.28 
$80,000 + 0.25 
Mean # visits to G.P. in last 12 months 3.25 
Proportion Engaging In (last 12 months):  
P.S.A. Test (Men>40) 0.32 
Mammogram (Women>35) 0.33 
N 25,787,334 (survey: 130880) 
 
Some of the variables in Table 7, such as number of visits in the last 12 months and 
employment status, are time-dependent.  Therefore, I examined not only the determinants 
for use of those who have undergone a PSA test or mammogram ever in their life, but 
also those who have demanded one of these screens in the last 12 months.  This also 
provides some insight on whether individuals adhere to recommendations provided by 
organizations such as the American Cancer Society to undergo these screens on an annual 
basis.   
 
Table 8 provides a first look at the relationship between screening and several predictors.  
Not all of the relationships are monotonic; however, it is evident that the likelihood of 
undergoing a PSA test or mammography increases with the number of doctor visits, age, 
and sickness.  However, the relationship of these medical screens with education and 
income is uncertain. 
 
There are a few figures that are peculiar: 9% of men report having a PSA test in the past 
year without having a doctor’s visit.  This result is perhaps due to men having urologist 
appointments scheduled for several months after their GP’s recommendation.  This may 
also partly explain the 15% of women who report having a mammogram in the last year 
without having a doctor’s visit.  Additionally, free-standing mammography clinics have 
become more widespread in the past several years in Canada, which may be captured in 
this result. 
 
Fewer than half of men aged 50-69 had a PSA test in the last 12 months.  This may 
reflect awareness of the uncertainty surrounding PSA screening, in addition to other 
predictors.  Only slightly more than half of women are following current guidelines by 
the CTFPHC and Canadian Cancer Society, i.e. they have had a mammogram in the last 
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12 months.  This shows that despite public awareness of breast cancer and mammography 
screening, uptake is far below target levels. 
Table 8 – Cross-tabs of screening and several predictors 
 PSA ever PSA last 
year 
Mammogram 
ever 
Mammogram 
last year 
# doc visits last year    
0 0.23 0.09 0.48 0.15 
1 0.43 0.31 0.61 0.31 
2 0.47 0.37 0.66 0.35 
3 0.49 0.38 0.69 0.38 
4 0.55 0.44 0.72 0.40 
5-9 0.55 0.43 0.71 0.40 
10-19 0.57 0.43 0.69 0.39 
20+ 0.55 0.43 0.69 0.37 
Age     
40-49 0.20 0.13 0.55 0.27 
50-59 0.50 0.36 0.86 0.52 
60-69 0.63 0.49 0.88 0.50 
70+ 0.67 0.49 0.73 0.30 
Self-perceived health     
Excellent 0.39 0.28 0.57 0.30 
Very good 0.43 0.31 0.63 0.33 
Good 0.44 0.32 0.68 0.35 
Fair 0.50 0.37 0.72 0.36 
Poor 0.55 0.42 0.70 0.35 
Education     
Less than High School 0.48 0.66 0.69 0.34 
High School grad 0.39 0.71 0.63 0.33 
Some post-secondary 0.44 0.69 0.65 0.32 
Post-secondary grad 0.42 0.69 0.62 0.33 
Income     
No income 0.64 0.49 0.73 0.38 
Less than $15,000 0.38 0.25 0.65 0.29 
$15,000 to $29,999 0.46 0.32 0.67 0.32 
$30,000 to $49,999 0.45 0.33 0.66 0.35 
$50,000 to $79,999 0.42 0.31 0.62 0.34 
$80,000 + 0.42 0.30 0.60 0.34 
 
To further explore the relationship between the probability of undergoing a PSA test or 
mammogram and various determinants, a probit regression was performed where the 
binary dependent variable was the use of the medical screen; the dependent variable took 
the value ‘0’ if the individual had not undergone the PSA test or mammography and ‘1’ if 
they had.  The explanatory variables included socio-economic, geographic, health status 
and education.  The coefficients are shown in Table 9; a full list of the explanatory 
variables and the econometric method is provided in Appendix C. 
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The two most consistent predictors of PSA screening among men aged 40 or older are 
age and number of medical consultations in the last 12 months.  Men in their 50s, 60s, 
and older are much more likely to undergo a PSA test. The probability of undergoing a 
PSA test increases with the number of medical consultations but the incremental increase 
after 2 visits is negligible.  Additionally, men who describe themselves in poor or fair 
health are less likely to undergo a PSA test.  Visible minorities are also less likely than 
white men to have had a PSA test.  The probability of PSA test use was significantly 
higher for those men in the top two income quartiles.  Married men and men in common-
law relationships were also more likely to have had a PSA test.  There were only minor 
differences in the predictors of men undergoing a PSA test in the last 12 months vs. men 
undergoing a PSA test ever in their life, as shown in Appendix C.  Men in Manitoba and 
New Brunswick were, ceteris paribus, the most likely to undergo a PSA test, whereas 
those in the Yukon were the least likely, even when controlling for health region 
idiosyncrasies.  At the time of the CCHS survey, provinces were not consistent in funding 
of PSA tests - British Columbia and Alberta did not fund the test unless the patient had 
noticeable symptoms, whereas Manitoba and some other provinces funded the test 
unconditionallyxviii.  Although men in Manitoba and New Brunswick, two of the 
provinces that fully funded PSA testing for men over 50, had a significantly higher 
probability of undergoing a PSA test, it is difficult to conclude that provincial funding 
strategies had significant impact on probability of undergoing a PSA test. 
 
As shown in Table 9, for women over 35, the two most consistent predictors of 
undergoing a mammogram were age and number of medical consultations in the last 12 
months.  Women aged 35-40 were significantly less likely and women in their 50s and 
60s were significantly more likely to have a mammogram than women in their 40s.  The 
probability of undergoing a mammogram increases with number of medical visits; 
however, it levels off after 4 visits.    Married women were more likely to have had a 
mammogram.  Women residing in the Yukon were significantly less likely to have a 
mammogram.  Results were generally the same for the probability of having a 
mammogram in the last year vs. the probability of ever having a mammogram; the only 
                                                 
xviii “The patchwork of care in Canada”, The Globe and Mail, Brian Laghi. 4 December 2002. 
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exceptions were education and income - the probability increased with income and 
education; however, the coefficients were generally only significant for the probability of 
ever having a mammogram, and not the probability of having a mammogram in the last 
year. 
 
Table 9 – Coefficients of probit regressions 
Variable Mammogram last 
year 
Mammogram last 
year aged 40-49 
PSA test last 
year 
Age    
35-40 -0.75*   
40-49 (omitted)    
50-59 0.68*  0.76* 
60-69 0.67*  1.04* 
70+ 0.35*  1.17* 
Sick -0.09* 0.07 -0.15* 
Health Utility Index 0.11 0.14 0.04 
Visible Minority 0.02 0.04 -0.18* 
Immigrant 0.04 0.05 -0.06 
Not Employed 0.01 0.03 0.06 
Education    
Less than secondary school   
(omitted) 
   
Secondary school grad 0.05 0.10 0.00 
Some post-secondary 0.07 0.16 0.00 
Post-secondary grad 0.10* 0.12 0.03 
Marital Status     
Single (omitted)    
Married 0.17* 0.21* 0.19* 
Common-law 0.01 0.02 0.16* 
Widowed/Separated/Divorced 0.05 0.07 -0.03 
Income    
1st Quartile (omitted)    
2nd Quartile -0.05 -0.20* 0.08 
3rd Quartile 0.08 0.05 0.27* 
4th Quartile 0.08 0.08 0.34* 
# medical consultations in last 12 
months 
   
0 (omitted)    
1 0.65* 0.68* 0.89* 
2 0.83* 0.86* 1.12* 
3 0.93* 0.98* 1.08* 
4 1.02* 1.14* 1.11* 
5-9 0.97* 1.10* 1.24* 
10-19 1.05* 1.18* 1.18* 
20+ 1.12* 1.19* 1.46* 
Province    
B.C. (omitted)    
Alberta -0.02 -0.04 -0.12 
Saskatchewan -0.05 -0.38* 0.03 
Manitoba -0.05 -0.29* 0.27* 
Ontario -0.02 -0.22* 0.15 
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Quebec -0.07 -0.30* 0.05 
New Brunswick 0.05 -0.10 0.24* 
Nova Scotia 0.12 0.13 0.15 
Newfoundland -0.18 -0.24 -0.16 
P.E.I. 0.02 0.09 0.16 
Yukon -0.28* -0.46* -0.34* 
Health Region Group    
Group A -0.04 -0.04 -0.19 
Group B -0.03 -0.11 -0.09 
Group C (omitted)    
Group D  -0.07 0.02 -0.11 
Group E -0.08 -0.15 -0.26* 
Group F -0.05 0.01 0.03 
Group G -0.16* -0.29* -0.27* 
Group H -0.06 -0.10 -0.15 
Group I -0.09 -0.09 -0.22* 
Group J -0.02 -0.10 -0.22* 
Constant -1.68* -1.65* -2.37* 
Note: * - significant at 5% level. 
As mentioned earlier, both PSA testing in men and mammography for women aged 40-49 
is surrounded with much uncertainty.  Therefore, a probit regression was performed for 
women aged 40-49 to analyze the determinants of uptake of mammography.  Unlike the 
predictors of mammography for women aged over 35 years, self-reported poor health was 
a not a significant factor in predicting uptake for women aged 40-49.  On the other hand, 
women aged 40-49 in the lower-middle income quartile were significantly less likely to 
have had a mammogram in the last year than women in the lowest income quartile. 
 
Additionally, women aged 40-49 who resided in Saskatchewan, Manitoba, Ontario, 
Quebec or Yukon were significantly less likely to have had a mammogram in the last 
year than were women in British Columbia. 
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7 Conclusions 
This paper has shown that the rate and determinants of uptake of medical screens depend 
on the uncertainty surrounding the procedure.  The rate of uptake for mammography of 
women aged 50-59, a screen with relatively low uncertainty, was much higher that the 
rates of uptake for mammography for women aged 40-49 and PSA testing in men. 
 
The significant determinants of uptake of PSA tests by men over 40 are age, self-reported 
health, being a member of a visible minority, marital status, income, number of doctor 
visits and geographic location.  The significant determinants of uptake of mammography 
for women over 35 are age, self-reported health, education, marital status, number of 
doctor visits and health region group.  Income and province of residence were also 
significant determinants for women aged 40-49. 
 
These results for the Canadian population have confirmed the findings of earlier analyses.  
Wu42 found that health status was a strong determinant of who undergoes screening.  This 
study found that the probability of undergoing a PSA test or a mammogram in the last 
year were significantly reduced if the individual’s self-reported health status was ‘poor’ 
or ‘fair’.  The findings of this paper were also broadly similar to those of Ruffin et al.37 
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8 Appendix A – CTFPHC and USPSTF ranking 
Table 10 - Ranking methodology of CTFPHC and USPSTF 
CTFPHC USPSTF 
“DOs” 
• A – Good Evidence to include 
in PHE 
• B – Fair Evidence to include in 
PHE 
“Conflicting” 
• C – Insufficient Evidence 
 
Strongest Evidence 
 
 
↓ 
 
 
 
Weakest Evidence 
“DON’Ts” 
• D – Fair Evidence to exclude 
from PHE 
• E – Good Evidence to exclude 
from PHE 
 
• A – Strongly recommend for 
eligible patients  
• B – Recommend for eligible 
patients 
 
• C – No recommendation for or 
against 
• D – Recommend against 
routine provision for 
asymptomatic patients 
 
Insufficient Evidence to make 
recommendation 
• Ixix – Insufficient / poor quality 
evidence 
• I – Insufficient / poor quality 
evidence 
 
9 Appendix B – Sample vignette 
 
                                                 
xix The CTFPHC recently replaced the ‘C’ recommendation with the ‘I’ recommendation; however, the 
changes were not made retroactively. 
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10 Appendix C – Full Probit results 
A probit model was used to examine the determinants of use of the PSA test and 
mammography.  The specification of the probit model is as follows: 
P (y=1 | x) = G (β0 + xβ) 
where G(z) = φ (z) ≡ ∫ φ (v) δv and φ (z) = (2π)-1/2exp(-z2/2) with 0 ≤ (y=1 | x) ≤ 1 
 
The following four probit regressions were performed: 
1. P (PSA_ever=1 | x) = G (β0 + xβ) 
2. P (PSA_1yr=1 | x) = G (β0 + xβ) 
3. P (mamm_ever=1 | x) = G (β0 + xβ) 
4. P (mamm_1yr=1 | x) = G (β0 + xβ) 
The same vector of explanatory variables, x, was used for all regressions.  A full 
description of the variables is provided in Appendix C. 
 
The following tables present the full results of the probit estimations. 
Table 11 – Probit results for determinants of use of PSA test (ever) 
Variable PSA 
ever 
Robust 
std. 
error 
z-statistic P>z 95% Confidence 
Interval 
Age       
40-49 (omitted)       
50-59 0.83 0.03 26.76* 0.00 0.77 0.89 
60-69 1.14 0.04 27.78* 0.00 1.06 1.22 
70+ 1.31 0.06 22.65* 0.00 1.20 1.43 
Sick -0.14 0.04 -3.53* 0.00 -0.22 -0.06 
Health Utility Index 0.08 0.07 1.19 0.24 -0.05 0.22 
Visible Minority -0.27 0.06 -4.28* 0.00 -0.39 -0.14 
Immigrant -0.14 0.04 -3.37* 0.00 -0.22 -0.06 
Not Employed 0.09 0.04 2.31* 0.02 0.01 0.17 
Education       
Less than secondary school   
(omitted) 
      
Secondary school grad 0.00 0.04 0.00 1.00 -0.08 0.08 
Some post-secondary 0.13 0.06 2.35* 0.02 0.02 0.24 
Post-secondary grad 0.07 0.03 2.10* 0.04 0.00 0.14 
Marital Status        
Single (omitted)       
Married 0.26 0.04 5.87* 0.00 0.17 0.34 
Common-law 0.22 0.06 3.48* 0.00 0.09 0.34 
Widowed/Separated/Divorced 0.10 0.05 2.02* 0.04 0.00 0.20 
 39
Income       
1st Quartile (omitted)       
2nd Quartile 0.00 0.05 0.08 0.93 -0.10 0.11 
3rd Quartile 0.22 0.05 4.27* 0.00 0.12 0.32 
4th Quartile 0.30 0.06 5.33* 0.00 0.19 0.40 
# medical consultations in last 12 
months 
      
0 (omitted)       
1 0.50 0.04 11.86* 0.00 0.42 0.58 
2 0.62 0.05 13.67* 0.00 0.53 0.70 
3 0.64 0.05 12.88* 0.00 0.54 0.74 
4 0.68 0.05 12.99* 0.00 0.58 0.79 
5-9 0.74 0.05 16.10* 0.00 0.65 0.83 
10-19 0.76 0.06 13.07* 0.00 0.65 0.88 
20+ 1.05 0.09 12.04* 0.00 0.88 1.22 
Province       
B.C. (omitted)       
Alberta -0.20 0.07 -2.80* 0.01 -0.34 -0.06 
Saskatchewan -0.07 0.08 -0.86 0.39 -0.23 0.09 
Manitoba 0.15 0.08 1.75 0.08 -0.02 0.31 
Ontario 0.10 0.07 1.52 0.13 -0.03 0.23 
Quebec -0.03 0.08 -0.41 0.68 -0.18 0.12 
New Brunswick 0.18 0.09 2.06* 0.04 0.01 0.34 
Nova Scotia 0.08 0.09 0.89 0.37 -0.09 0.25 
Newfoundland -0.19 0.10 -1.86 0.06 -0.40 0.01 
P.E.I. 0.05 0.11 0.50 0.62 -0.16 0.26 
Yukon -0.30 0.10 -2.91* 0.00 -0.50 -0.10 
Health Region Group       
Group A -0.15 0.09 -1.78 0.08 -0.32 0.02 
Group B -0.12 0.07 -1.65 0.10 -0.27 0.02 
Group C (omitted)       
Group D  -0.14 0.10 -1.38 0.17 -0.34 0.06 
Group E -0.24 0.09 -2.51* 0.01 -0.42 -0.05 
Group F -0.02 0.07 -0.35 0.73 -0.15 0.10 
Group G -0.23 0.08 -2.76* 0.01 -0.39 -0.07 
Group H -0.13 0.09 -1.51 0.13 -0.30 0.04 
Group I -0.21 0.08 -2.57* 0.01 -0.37 -0.05 
Group J -0.18 0.08 -2.11* 0.04 -0.34 -0.01 
Constant -1.69 0.10 -17.19* 0.00 -1.89 -1.50 
Note: * - significant at 5% level. 
Table 12 - Probit results for determinants of use of PSA test (last year) 
Variable PSA 
last 
yr 
Robust 
std. 
error 
z-statistic P>z 95% Confidence 
Interval 
Age       
40-49 (omitted)       
50-59 0.76 0.03 22.91* 0.00 0.70 0.83 
60-69 1.04 0.04 24.46* 0.00 0.95 1.12 
70+ 1.17 0.06 19.87* 0.00 1.05 1.28 
Sick -0.15 0.04 -3.51* 0.00 -0.23 -0.06 
Health Utility Index 0.04 0.07 0.54 0.59 -0.11 0.18 
Visible Minority -0.18 0.06 -2.84* 0.00 -0.31 -0.06 
Immigrant -0.06 0.04 -1.47 0.14 -0.14 0.02 
Not Employed 0.06 0.04 1.53 0.13 -0.02 0.14 
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Education       
Less than secondary school   
(omitted) 
      
Secondary school grad 0.00 0.04 0.01 0.99 -0.08 0.08 
Some post-secondary 0.00 0.06 0.02 0.99 -0.11 0.12 
Post-secondary grad 0.03 0.03 0.89 0.38 -0.04 0.10 
Marital Status        
Single (omitted)       
Married 0.19 0.05 3.85* 0.00 0.09 0.28 
Common-law 0.16 0.07 2.34* 0.02 0.03 0.30 
Widowed/Separated/Divorced -0.03 0.06 -0.50 0.62 -0.14 0.08 
Income       
1st Quartile (omitted)       
2nd Quartile 0.08 0.06 1.44 0.15 -0.03 0.19 
3rd Quartile 0.27 0.05 4.96* 0.00 0.16 0.37 
4th Quartile 0.34 0.06 5.90* 0.00 0.23 0.46 
# medical consultations in last 12 
months 
      
0 (omitted)       
1 0.89 0.05 17.23* 0.00 0.79 0.99 
2 1.12 0.05 20.76* 0.00 1.01 1.22 
3 1.08 0.06 18.53* 0.00 0.96 1.19 
4 1.11 0.06 18.33* 0.00 0.99 1.23 
5-9 1.24 0.05 22.80* 0.00 1.13 1.35 
10-19 1.18 0.06 18.48* 0.00 1.05 1.30 
20+ 1.46 0.09 15.47* 0.00 1.27 1.64 
Province       
B.C. (omitted)       
Alberta -0.12 0.08 -1.50 0.13 -0.27 0.03 
Saskatchewan 0.03 0.09 0.31 0.76 -0.15 0.20 
Manitoba 0.27 0.09 2.98* 0.00 0.09 0.44 
Ontario 0.15 0.07 2.08* 0.04 0.01 0.28 
Quebec 0.05 0.08 0.63 0.53 -0.11 0.21 
New Brunswick 0.24 0.09 2.67* 0.01 0.06 0.42 
Nova Scotia 0.15 0.09 1.64 0.10 -0.03 0.34 
Newfoundland -0.16 0.11 -1.49 0.14 -0.38 0.05 
P.E.I. 0.16 0.12 1.28 0.20 -0.08 0.40 
Yukon -0.34 0.11 -3.03* 0.00 -0.55 -0.12 
Health Region Group       
Group A -0.19 0.09 -2.06* 0.04 -0.36 -0.01 
Group B -0.09 0.08 -1.14 0.25 -0.24 0.06 
Group C (omitted)       
Group D  -0.11 0.11 -1.01 0.31 -0.32 0.10 
Group E -0.26 0.10 -2.68* 0.01 -0.46 -0.07 
Group F 0.03 0.07 0.37 0.71 -0.11 0.16 
Group G -0.27 0.09 -3.06* 0.00 -0.45 -0.10 
Group H -0.15 0.09 -1.68 0.09 -0.33 0.03 
Group I -0.22 0.09 -2.53* 0.01 -0.38 -0.05 
Group J -0.22 0.09 -2.50* 0.01 -0.40 -0.05 
Constant -2.37 0.11 -21.78* 0.00 -2.58 -2.16 
Note: * - significant at 5% level. 
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Table 13 - Probit results for determinants of use of mammogram (ever) 
Variable Mammogram 
ever 
Robust 
std. 
error 
z-
statistic 
P>z 95% 
Confidence 
Interval 
Age       
35-40 -0.93 0.03 -28.38* 0.00 -0.99 -0.86 
40-49 (omitted)       
50-59 1.00 0.03 30.45* 0.00 0.93 1.06 
60-69 1.14 0.04 25.76* 0.00 1.05 1.22 
70+ 0.84 0.06 15.20* 0.00 0.73 0.95 
Sick -0.06 0.04 -1.41 0.16 -0.14 0.02 
Health Utility Index -0.09 0.07 -1.33 0.19 -0.23 0.05 
Visible Minority -0.15 0.05 -2.87* 0.00 -0.26 -0.05 
Immigrant 0.04 0.04 0.96 0.34 -0.04 0.11 
Not Employed -0.07 0.03 -1.94 0.05 -0.13 0.00 
Education       
Less than secondary school   
(omitted) 
      
Secondary school grad 0.04 0.04 1.11 0.27 -0.03 0.12 
Some post-secondary 0.13 0.05 2.44* 0.02 0.02 0.23 
Post-secondary grad 0.12 0.04 3.34* 0.00 0.05 0.19 
Marital Status        
Single (omitted)       
Married 0.10 0.04 2.49* 0.01 0.02 0.18 
Common-law 0.06 0.06 1.04 0.30 -0.05 0.17 
Widowed/Separated/Divorced 0.05 0.04 1.20 0.23 -0.03 0.14 
Income       
1st Quartile (omitted)       
2nd Quartile -0.02 0.04 -0.44 0.66 -0.10 0.06 
3rd Quartile 0.14 0.04 3.29* 0.00 0.06 0.23 
4th Quartile 0.14 0.05 2.92* 0.00 0.05 0.24 
# medical consultations in last 12 
months 
      
0 (omitted)       
1 0.41 0.04 9.37* 0.00 0.32 0.49 
2 0.54 0.04 11.99* 0.00 0.45 0.62 
3 0.63 0.05 12.84* 0.00 0.54 0.73 
4 0.71 0.05 13.85* 0.00 0.61 0.81 
5-9 0.73 0.04 16.57* 0.00 0.64 0.81 
10-19 0.70 0.05 13.38* 0.00 0.60 0.81 
20+ 0.79 0.07 10.74* 0.00 0.65 0.93 
Province       
B.C. (omitted)       
Alberta -0.01 0.06 -0.12 0.90 -0.14 0.12 
Saskatchewan -0.17 0.07 -2.36* 0.02 -0.31 -0.03 
Manitoba -0.09 0.08 -1.15 0.25 -0.24 0.06 
Ontario -0.10 0.06 -1.62 0.10 -0.21 0.02 
Quebec 0.07 0.07 1.04 0.30 -0.06 0.20 
New Brunswick 0.05 0.08 0.62 0.53 -0.11 0.20 
Nova Scotia -0.14 0.08 -1.84 0.07 -0.30 0.01 
Newfoundland -0.35 0.09 -3.95* 0.00 -0.53 -0.18 
P.E.I. -0.19 0.09 -2.13* 0.03 -0.36 -0.01 
Yukon -0.35 0.09 -3.79* 0.00 -0.53 -0.17 
Health Region Group       
Group A 0.11 0.08 1.48 0.14 -0.04 0.27 
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Group B 0.05 0.07 0.84 0.40 -0.07 0.18 
Group C (omitted)       
Group D  0.03 0.09 0.32 0.75 -0.15 0.21 
Group E 0.11 0.08 1.32 0.19 -0.05 0.28 
Group F 0.12 0.06 1.89 0.06 0.00 0.24 
Group G 0.02 0.08 0.31 0.75 -0.12 0.17 
Group H 0.04 0.08 0.56 0.58 -0.11 0.19 
Group I 0.07 0.07 1.01 0.31 -0.07 0.22 
Group J 0.17 0.08 2.15* 0.03 0.02 0.32 
Constant -0.57 0.09 -6.02* 0.00 -0.75 -0.38 
Note: * - significant at 5% level. 
Table 14 - Probit results for determinants of use of mammogram (last year) 
Variable Mammogram 
last yr 
Robust 
std. 
error 
z-
statistic 
P>z 95% 
Confidence 
Interval 
Age       
35-40 -0.75 0.04 -17.90* 0.00 -0.84 -0.67 
40-49 (omitted)       
50-59 0.68 0.03 22.93* 0.00 0.62 0.74 
60-69 0.67 0.04 17.41* 0.00 0.59 0.75 
70+ 0.35 0.05 6.95* 0.00 0.25 0.45 
Sick -0.09 0.04 -2.26* 0.02 -0.16 -0.01 
Health Utility Index 0.11 0.07 1.68 0.09 -0.02 0.24 
Visible Minority 0.02 0.05 0.35 0.72 -0.08 0.12 
Immigrant 0.04 0.04 1.12 0.26 -0.03 0.11 
Not Employed 0.01 0.03 0.40 0.69 -0.05 0.07 
Education       
Less than secondary school   
(omitted) 
      
Secondary school grad 0.05 0.04 1.43 0.15 -0.02 0.12 
Some post-secondary 0.07 0.05 1.43 0.15 -0.03 0.17 
Post-secondary grad 0.10 0.03 3.05* 0.00 0.03 0.16 
Marital Status        
Single (omitted)       
Married 0.17 0.04 3.98* 0.00 0.09 0.26 
Common-law 0.01 0.06 0.14 0.89 -0.11 0.13 
Widowed/Separated/Divorced 0.05 0.05 1.00 0.32 -0.04 0.13 
Income       
1st Quartile (omitted)       
2nd Quartile -0.05 0.04 -1.32 0.19 -0.14 0.03 
3rd Quartile 0.08 0.04 1.84 0.07 -0.01 0.16 
4th Quartile 0.08 0.05 1.64 0.10 -0.02 0.17 
# medical consultations in last 12 
months 
      
0 (omitted)       
1 0.65 0.05 12.61* 0.00 0.55 0.75 
2 0.83 0.05 16.00* 0.00 0.73 0.93 
3 0.93 0.05 16.89* 0.00 0.82 1.04 
4 1.02 0.06 17.95* 0.00 0.90 1.13 
905-9 0.97 0.05 18.83* 0.00 0.87 1.07 
10-19 1.05 0.06 18.18* 0.00 0.93 1.16 
20+ 1.12 0.08 14.42* 0.00 0.97 1.27 
Province       
B.C. (omitted)       
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Alberta -0.02 0.06 -0.38 0.70 -0.14 0.10 
Saskatchewan -0.05 0.07 -0.75 0.46 -0.19 0.08 
Manitoba -0.05 0.07 -0.64 0.52 -0.19 0.10 
Ontario -0.02 0.06 -0.41 0.68 -0.13 0.09 
Quebec -0.07 0.06 -1.13 0.26 -0.20 0.05 
New Brunswick 0.05 0.07 0.71 0.48 -0.09 0.20 
Nova Scotia 0.12 0.07 1.59 0.11 -0.03 0.26 
Newfoundland -0.18 0.09 -2.05* 0.04 -0.35 -0.01 
P.E.I. 0.02 0.09 0.27 0.79 -0.14 0.19 
Yukon -0.28 0.09 -3.03* 0.00 -0.46 -0.10 
Health Region Group       
Group A -0.04 0.07 -0.52 0.60 -0.18 0.10 
Group B -0.03 0.06 -0.51 0.61 -0.15 0.09 
Group C (omitted)       
Group D  -0.07 0.09 -0.80 0.43 -0.24 0.10 
Group E -0.08 0.08 -0.97 0.34 -0.23 0.08 
Group F -0.05 0.06 -0.84 0.40 -0.16 0.06 
Group G -0.16 0.07 -2.21* 0.03 -0.30 -0.02 
Group H -0.06 0.07 -0.88 0.38 -0.20 0.08 
Group I -0.09 0.07 -1.36 0.18 -0.23 0.04 
Group J -0.02 0.07 -0.22 0.83 -0.16 0.13 
Constant -1.68 0.10 -16.83* 0.00 -1.88 -1.49 
Note: * - significant at 5% level. 
Table 15 - Probit results for determinants of use of mammogram for women aged 40-49 (ever) 
Variable Mammogram 
ever aged 40-
49 
Robust 
std. 
error 
z-
statistic 
P>z 95% 
Confidence 
Interval 
Sick 0.05 0.07 0.64 0.52 -0.09 0.18 
Health Utility Index -0.15 0.12 -1.31 0.19 -0.38 0.07 
Visible Minority -0.13 0.08 -1.61 0.11 -0.29 0.03 
Immigrant 0.10 0.07 1.58 0.12 -0.03 0.23 
Not Employed -0.13 0.06 -2.24* 0.03 -0.24 -0.02 
Education       
Less than secondary school   
(omitted) 
      
Secondary school grad -0.01 0.06 -0.16 0.87 -0.13 0.11 
Some post-secondary 0.06 0.08 0.74 0.46 -0.10 0.22 
Post-secondary grad 0.02 0.06 0.36 0.72 -0.09 0.13 
Marital Status        
Single (omitted)       
Married 0.12 0.06 1.96* 0.05 0.00 0.24 
Common-law 0.11 0.08 1.35 0.18 -0.05 0.26 
Widowed/Separated/Divorced 0.15 0.07 2.32* 0.02 0.02 0.29 
Income       
1st Quartile (omitted)       
2nd Quartile -0.04 0.07 -0.56 0.58 -0.18 0.10 
3rd Quartile 0.22 0.07 3.30* 0.00 0.09 0.35 
4th Quartile 0.27 0.07 3.78* 0.00 0.13 0.41 
# medical consultations in last 12 
months 
      
0 (omitted)       
1 0.32 0.06 5.03* 0.00 0.19 0.44 
2 0.46 0.07 6.94* 0.00 0.33 0.59 
3 0.60 0.07 8.27* 0.00 0.45 0.74 
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4 0.69 0.08 8.53* 0.00 0.53 0.85 
905-9 0.68 0.07 10.29* 0.00 0.55 0.82 
10-19 0.72 0.08 8.88* 0.00 0.56 0.87 
20+ 0.79 0.10 7.64* 0.00 0.59 0.99 
Province       
B.C. (omitted)       
Alberta -0.03 0.10 -0.30 0.77 -0.21 0.16 
Saskatchewan -0.26 0.11 -2.35* 0.02 -0.48 -0.04 
Manitoba -0.13 0.12 -1.09 0.28 -0.35 0.10 
Ontario -0.14 0.09 -1.53 0.13 -0.31 0.04 
Quebec 0.01 0.10 0.05 0.96 -0.20 0.21 
New Brunswick 0.13 0.12 1.13 0.26 -0.10 0.36 
Nova Scotia -0.01 0.12 -0.10 0.92 -0.25 0.22 
Newfoundland -0.15 0.14 -1.07 0.28 -0.42 0.12 
P.E.I. -0.09 0.14 -0.65 0.52 -0.38 0.19 
Yukon -0.50 0.13 -3.79* 0.00 -0.77 -0.24 
Health Region Group       
Group A 0.10 0.11 0.84 0.40 -0.13 0.32 
Group B 0.01 0.10 0.09 0.93 -0.18 0.20 
Group C (omitted)       
Group D  -0.06 0.14 -0.46 0.65 -0.33 0.21 
Group E -0.01 0.13 -0.11 0.91 -0.27 0.24 
Group F 0.15 0.09 1.63 0.10 -0.03 0.34 
Group G -0.13 0.11 -1.16 0.25 -0.35 0.09 
Group H -0.12 0.12 -1.04 0.30 -0.35 0.11 
Group I -0.02 0.11 -0.19 0.85 -0.23 0.19 
Group J 0.09 0.12 0.77 0.44 -0.14 0.32 
Constant -0.41 0.15 -2.74* 0.01 -0.71 -0.12 
Note: * - significant at 5% level. 
Table 16 - Probit results for determinants of use of mammogram for women aged 40-49 ( last year) 
Variable Mammogram 
last yr aged 
40-49 
Robust 
std. 
error 
z-
statistic 
P>z 95% 
Confidence 
Interval 
Sick 0.07 0.08 0.79 0.43 -0.10 0.23 
Health Utility Index 0.14 0.13 1.04 0.30 -0.12 0.40 
Visible Minority 0.04 0.09 0.41 0.68 -0.14 0.21 
Immigrant 0.05 0.07 0.64 0.52 -0.09 0.19 
Not Employed 0.03 0.06 0.53 0.59 -0.09 0.15 
Education       
Less than secondary school   
(omitted) 
      
Secondary school grad 0.10 0.07 1.37 0.17 -0.04 0.23 
Some post-secondary 0.16 0.10 1.68 0.09 -0.03 0.35 
Post-secondary grad 0.12 0.06 1.87 0.06 -0.01 0.25 
Marital Status        
Single (omitted)       
Married 0.21 0.07 3.11* 0.00 0.08 0.35 
Common-law 0.02 0.09 0.17 0.86 -0.16 0.20 
Widowed/Separated/Divorced 0.07 0.08 0.94 0.35 -0.08 0.22 
Income       
1st Quartile (omitted)       
2nd Quartile -0.20 0.08 -2.52* 0.01 -0.36 -0.04 
3rd Quartile 0.05 0.08 0.65 0.51 -0.10 0.20 
4th Quartile 0.08 0.08 1.04 0.30 -0.07 0.24 
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# medical consultations in last 12 
months 
      
0 (omitted)       
1 0.68 0.09 7.69* 0.00 0.50 0.85 
2 0.86 0.09 9.55* 0.00 0.68 1.03 
3 0.98 0.10 10.23* 0.00 0.79 1.17 
4 1.14 0.10 11.02* 0.00 0.94 1.34 
905-9 1.10 0.09 12.01* 0.00 0.92 1.28 
10-19 1.18 0.10 11.30* 0.00 0.98 1.39 
20+ 1.19 0.13 9.22* 0.00 0.94 1.45 
Province       
B.C. (omitted)       
Alberta -0.04 0.10 -0.44 0.66 -0.24 0.15 
Saskatchewan -0.38 0.12 -3.04* 0.00 -0.62 -0.13 
Manitoba -0.29 0.13 -2.29* 0.02 -0.53 -0.04 
Ontario -0.22 0.09 -2.36* 0.02 -0.39 -0.04 
Quebec -0.30 0.11 -2.76* 0.01 -0.52 -0.09 
New Brunswick -0.10 0.12 -0.84 0.40 -0.34 0.14 
Nova Scotia 0.13 0.12 1.09 0.28 -0.11 0.38 
Newfoundland -0.24 0.15 -1.59 0.11 -0.54 0.06 
P.E.I. 0.09 0.16 0.57 0.57 -0.22 0.39 
Yukon -0.46 0.15 -3.12* 0.00 -0.75 -0.17 
Health Region Group       
Group A -0.04 0.12 -0.36 0.72 -0.28 0.19 
Group B -0.11 0.10 -1.08 0.28 -0.30 0.09 
Group C (omitted)       
Group D  0.02 0.15 0.10 0.92 -0.27 0.30 
Group E -0.15 0.14 -1.06 0.29 -0.42 0.12 
Group F 0.01 0.10 0.13 0.90 -0.18 0.20 
Group G -0.29 0.12 -2.43* 0.02 -0.52 -0.06 
Group H -0.10 0.12 -0.80 0.43 -0.33 0.14 
Group I -0.09 0.11 -0.81 0.42 -0.31 0.13 
Group J -0.10 0.12 -0.86 0.39 -0.34 0.13 
Constant -1.65 0.19 -8.86* 0.00 -2.02 -1.29 
Note: * - significant at 5% level. 
 46
11 Appendix D - Description of variables 
All variables are derived from Canadian Community Health Survey (CCHS)xx, Cycle 1.1.  
The information was collected between September 2000 and November 2001.  The 
survey covers all health regions, provinces and territories.  The CCHS Survey collects 
responses from people aged 12 and over who live in private, occupied dwellings.  
Individuals living on Indian Reserves, Crown Lands, institutions, certain remote regions 
as well as full-time residents of the Canadian Armed Forces are excluded from the 
survey.  A national response rate of 84.7% was achieved.     All missing data was 
dropped from the sample. 
11.1 Weighting  
The CCHS is based on a complex design; it includes stratification, multiple stages of 
selection and unequal probabilities of selection of respondents.  The sample size of the 
CCHS is 133,880.  Each of these individuals “represents” several other people that are 
not in the sample.  Using these weights, the survey of 133,880 is extrapolated to a 
population of 25,787,334xxi.  The weighting was incorporated into all calculations in Stata 
using the subset of commands that specifically deals with survey data; in general the 
commands are the same but preceded by “svy” (i.e. svymean, svyprobit etc.).  Although 
the svy commands were used, clustering and stratification were not identified; therefore, 
the reported standard errors are slightly too small.  Consequently, z-stats that are close to 
2 may not be valid. 
 
Before releasing any results, users must determine the number of respondents that 
contributed to the calculation of the estimate.  If the number is less than 30, results should 
not be released.  This is not the case for any of the regressions in this analysis.  If the 
number is greater than 30, then the CCHS provides coefficient of variation tables to 
determine the acceptability of the results.  All the estimates in this analysis were found to 
                                                 
xx Available online via Statistics Canada at : http://www.statcan.ca/english/concepts/health/ 
xxi The exact weighting procedure can be found in Section 8 of the CCHS User’s Guide. 
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be ‘acceptable’, as defined in the CCHS User’s Guide.  See the CCHS User Guidexxii for 
more information. 
11.2 Dependent variables 
PSA_ever (relevant CCHS variable: PSAA_170) 
PSA_ever was set to ‘1’ if a man had ever had a PSA test in the past.  This survey 
question was only asked to men aged 40 and over. 
 
PSA_1yr (elevant CCHS variable: PSAA_172) 
PSA_1yr was set to ‘1’ if a man had undergone a PSA test in the last 12 months.  This 
survey question was only asked to men who answered ‘yes’ to PSAA_170 and who were 
aged 40 and over. 
 
Mamm_ever (relevant CCHS variable: mama_30) 
Mamm_ever was set to ‘1’ if a woman had ever undergone a mammogram in the past.  
This survey question was asked only to women aged 35 and over. 
 
Mamm_1yr (relevant CCHS variable: mama_32) 
Mamm_1yr was set to ‘1’ if a woman had undergone a mammogram in the last 12 
months.  This survey question was only asked to women who answered ‘yes’ to 
mama_30 and who were aged 35 and over. 
11.3 Explanatory variables 
Age (relevant CCHS variable: dhha_age) 
The questions regarding the PSA test were only asked to men aged 40 or over.  As such, 
for the probit regressions involving the PSA test, only men over 40 were included in the 
analysis.  The questions regarding mammography were only asked to women aged 35 or 
over.  Therefore, the probit regressions involving mammography incorporated only 
women 35 and older.  Binary variables were used for age and were defined as follows: 
• Age35 – set to ‘1’ if individual is aged 35-39, else ‘0’. 
                                                 
xxii http://sherlock.bib.umontreal.ca/ENQ-10325/doc/cchs2000-2001gid.pdf 
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• Age40 – set to ‘1’ if individual is aged 40-44, else ‘0’. 
• Age45 – set to ‘1’ if individual is aged 45-49, else ‘0’. 
• Age50 – set to ‘1’ if individual is aged 50-54, else ‘0’. 
• Age55 – set to ‘1’ if individual is aged 55-59, else ‘0’. 
• Age60 – set to ‘1’ if individual is aged 60-64, else ‘0’. 
• Age65 – set to ‘1’ if individual is aged 65-69, else ‘0’. 
• Age70 – set to ‘1’ if individual is aged 70-74, else ‘0’. 
• Age75 –  set to ‘1’ if individual is aged 75-79, else ‘0’. 
• Age80 –  set to ‘1’ if individual is aged 80+, else ‘0’. 
 
Sick (relevant CCHS variable: gena_01) 
‘Sick’ is a measure of self-reported health status.  Sick is set to ‘1’ is an individual 
reported themselves as being in fair or poor health; it is set to ‘0’ if an individual reported 
themselves as being in excellent, very good or good health. 
 
HUtility (relevant CCHS variable: huiadhsi) 
‘Hutility’ is the Health Utility Index.  It is a variable whose value is derived from the 
responses of several health related questions using the Comprehensive Health Status 
Measurement System.** 
 
Minority (relevant CCHS variable: sdcagrac) 
‘Minority’ is set to 1 if the individual is a member of a visual minority, else it is set to ‘0’. 
 
Immigrant (relevant CCHS variable: scdafimm)   
‘Immigrant’ is set to ‘1’ if the individual is an immigrant, else it is set to ‘0’. 
 
Not Employed (relevant CCHS variable: lbfagjst) 
‘NotEmployed’ is set to ‘1’ if the individual’s job status over the past year was “Without 
job, either looking or not looking”, else it is set to ‘0’. 
 
Education (relevant CCHS variable: eduadr04) 
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Binary variables were used to classify individuals in education groups as follows: 
• Educ1 – set to ‘1’ if individual has less than secondary school education, else ‘0’. 
• Educ2 – set to ‘1’ if individual has secondary school graduation, else ‘0’. 
• Educ3 – set to ‘1’ if individual has some post-secondary education, else ‘0’. 
• Educ4 – set to ‘1’ if individual has post-secondary graduation, else ‘0’. 
 
Marital Status (relevant CCHS variable: dhhagms) 
Binary variables were used to classify individuals in marital status groups as follows: 
• Married - set to ‘1’ if individual is married, else ‘0’. 
• CommonLaw - set to ‘1’ if individual is in a common-law relationship, else ‘0’. 
• Single - set to ‘1’ if individual is single, else ‘0’. 
• WidowSepDiv - set to ‘1’ if individual is a widowed, separated or divorced, else 
‘0’. 
 
Income quartile (relevant CCHS variable: incadia4) 
The income quartile variables are derived from responses to household income related 
questions in the CCHS survey. Binary variables were used to classify individuals in 
income quartiles as follows: 
• Incquart1 – set to ‘1’ if individual is in lowest income quartile, else ‘0’. 
• Incquart2 – set to ‘1’ if individual is in lower middle income quartile, else ‘0’. 
• Incquart3 – set to ‘1’ if individual is in upper middle income quartile, else ‘0’. 
• Incquart4 – set to ‘1’ if individual is in highest income quartile, else ‘0’. 
 
Medical Consultations (relevant CCHS variable: hcuagmdc) 
Binary variables were to represent the number of medical consultations with medical 
doctors in the last year as follows: 
• DocVisit0 – set to ‘1’ if the individual did not visit any medical doctors in the last 
12 months, else ‘0’. 
• DocVisit1 – set to ‘1’ if the individual visited a medical doctor once in the last 12 
months, else ‘0’. 
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• DocVisit2 – set to ‘1’ if the individual visited a medical doctor twice in the last 12 
months, else ‘0’. 
• DocVisit3 – set to ‘1’ if the individual visited a medical doctor three times in the 
last 12 months, else ‘0’. 
• DocVisit4 – set to ‘1’ if the individual visited a medical doctor four times in the 
last 12 months, else ‘0’. 
• DocVisit5 – set to ‘1’ if the individual visited a medical doctor 5-9 times in the 
last 12 months, else ‘0’. 
• DocVisit10 – set to ‘1’ if the individual visited a medical doctor 10-19 times in 
the last 12 months, else ‘0’. 
• DocVisit20 – set to ‘1’ if the individual visited a medical doctor 20+ times in the 
last 12 months, else ‘0’. 
 
Province (relevant CCHS variable: geoagprv) 
Binary variables were used to control for the effects of all provinces.  Variables were set 
to ‘1’ if the individual resided in the province, else ‘0’. 
 
StatCan Health Region (relevant CCHS variable: geoadpmf) 
Binary variables were defined to group health regions into peer groups.  CCHS has 
suggested these peer groupings based on their similar socio-economic characteristicsxxiii. 
 
 
 
Group 
 
 
Health Regions 
Group A 2406 - Région de Montréal-Centre 
3595 - City of Toronto Public Health Unit 
5916 - Vancouver 
5917 - Burnaby 
5919 - Richmond 
Group B 3551 - Ottawa Carleton Public Health Unit 
3553 - Peel Public Health Unit 
                                                 
xxiii For more information, see “Health Region Peer Groups”, Statistics Canada (Health Statistics Division).  
A PDF version is available at www.statcan.ca/english/freepub/ 82-221-XIE/01201/pdf/hrpeergroup.pdf 
 51
3570 - York Public Health Unit 
4804 - Calgary Regional Health Authority 
4810 - Capital Health Authority 
5907 - South Fraser Valley 
5908 - Simon Fraser 
5918 - North Shore 
Group C 2417 - Région du Nunavik 
2418 - Région des Terres-Cries-de-la-Baie-James 
4680 - Burntwood 
4711 - Northern Health Services Branch (K) Service Area 
6201 - Nunavut 
Group D 1004 - Health and Community Services Western Region 
1002 - Health and Community Services Eastern Region 
1003 - Health and Community Services Central Region 
1005 - Grenfell Regional Health Services Board 
1205 - Zone 5 
1305 - Region 5 
1306 - Region 6 
1307 - Region 7 
2411 - Région de la Gaspésie-Îles-de-la-Madeleine 
Group E 1102 - Rural Health Region 
1201 - Zone 1 
1202 - Zone 2 
3545 - Muskoka-Parry Sound Public Health Unit 
3563 - Timiskaming Public Health Unit 
4650 - Marquette 
4655 - South Westman 
4660 - Parkland 
4702 - Moose Jaw (B) Service Area 
4705 - Yorkton (E) Service Area 
4708 - Melfort (H) Service Area 
4709 - Prince Albert (I) Service Area 
4710 - North Battleford (J) Service Area 
Group F 1006 - Health Labrador Corporation 
2410 - Région du Nord-du-Québec 
4670 - Norman 
4690 - Churchill 
4813 - Mistahia Regional Health Authority 
4815 - Keeweetinok Lakes Regional Health Authority 
4816 - Northern Lights Regional Health Authority 
4817 - Northwestern Regional Health Authority 
5912 - Cariboo 
5913 - North West 
5914 - Peace Liard 
5915 - Northern Interior 
6001 - Yukon Territory 
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6101 - Northwest Territories 
Group G 
 
3539 - Huron Public Health Unit 
3549 - Northwestern Public Health Unit 
3554 - Perth Public Health Unit 
3557 - Renfrew Public Health Unit 
4620 - North Eastman 
4625 - South Eastman 
4630 - Interlake 
4640 - Central 
4701 - Weyburn (A) Service Area 
4703 - Swift Current (C) Service Area 
4707 - Rosetown (G) Service Area 
4801 - Chinook Regional Health Authority 
4802 - Palliser Health Authority 
4805 - Health Authority #5 
4806 - David Thompson Regional Health Authority 
4807 - East Central Health Authority 
4809 - Crossroads Regional Health Authority 
4811 - Aspen Regional Health Authority 
4812 - Lakeland Regional Health Authority 
4814 - Peace Regional Health Authority 
5901 - East Kootenay 
Group H 1001 - Health and Community Services St. John’s Region 
1203 - Zone 3 
1204 - Zone 4 
1302 - Region 2 
1304 - Region 4 
2401 - Région du Bas-Saint-Laurent 
2402 - Région du Saguenay - Lac-Saint-Jean 
2403 - Région de Québec 
2404 - Région de la Mauricie et Centre-du-Québec 
2405 - Région de l’Estrie 
2407 - Région de l’Outaouais 
2408 - Région de l’Abitibi-Témiscamingue 
2409 - Région de la Côte-Nord 
2412 - Région de la Chaudière-Appalaches 
2415 - Région des Laurentides 
2416 - Région de la Montérégie 
3526 - Algoma Public Health Unit 
3537 - Hamilton-Wentworth Public Health Unit 
3547 - North Bay Public Health Unit 
3556 - Porcupine Public Health Unit 
3561 - Sudbury Public Health Unit 
4610 - Winnipeg 
Group I 1101 - Urban Health Region 
1206 - Zone 6 
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1301 - Region 1 
1303 - Region 3 
2413 - Région de Laval 
2414 - Région de Lanaudière 
3527 - Brant Public Health Unit 
3531 - Elgin-St Thomas Public Health Unit 
3533 - Bruce-Grey-Owen Sound Public Health Unit 
3534 - Haldimand-Norfolk Public Health Unit 
3535 - Haliburton-Kawartha-Pine Ridge Public Health Unit 
3538 - Hastings and Prince Edward Public Health Unit 
3540 - Kent-Chatham Public Health Unit 
3541 - Kingston-Frontenac-Lennox and Addington Public Health Unit 
3542 - Lambton Public Health Unit 
3543 - Leeds-Grenville-Lanark Public Health Unit 
3544 - Middlesex-London Public Health Unit 
3546 - Niagara Public Health Unit 
3552 - Oxford Public Health Unit 
3555 - Peterborough Public Health Unit 
3558 - Eastern Ontario Public Health Unit 
3562 - Thunder Bay Public Health Unit 
3565 - Waterloo Public Health Unit 
3568 - Windsor-Essex Public Health Unit 
4615 - Brandon 
4704 - Regina (D) Service Area 
4706 - Saskatoon (F) Service Area 
5902 - West Kootenay-Boundary 
5903 - North Okanagan 
5904 - South Okanagan Similkameen 
5905 - Thompson 
5906 - Fraser Valley 
5910 - Central Vancouver Island 
5920 - Capital 
Group J 3530 - Durham Public Health Unit 
3536 - Halton Public Health Unit 
3560 - Simcoe Public Health Unit 
3566 - Wellington-Dufferin-Guelph Public Health Unit 
4803 - Headwaters Health Authority 
4808 - WestView Regional Health Authority 
5909 - Coast Garibaldi 
5911 - Upper Island/Central Coast 
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